NASDAQ · DFFN
Healthcare · Biotechnology
$4.40
Up+$0.41 (+10.28%)
Updated Sep 16, 2026, 5:22 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
DFFN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning DFFN.
DFFN research
Company profile and research snapshot.
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 16, 2022 | HC Wainwright & Co. | Buy | — |
| Nov 17, 2020 | HC Wainwright & Co. | Neutral | — |
| Nov 17, 2020 | H.C. Wainwright | Neutral | — |
| Dec 18, 2019 | H.C. Wainwright | Buy | — |
| Mar 21, 2018 | H.C. Wainwright | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 15, 2023
Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023
GlobeNewswire Inc. · Mar 30, 2023
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies
GlobeNewswire Inc. · Dec 16, 2022
LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting
GlobeNewswire Inc. · Dec 5, 2022
CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today sent a letter to its stockholders. The letter highlights the strength, experience and quality of the Company’s board of directors as it continues to take steps to unlock stockholder value through a strategic review process. The letter also summarizes the value-destructive acquisition offer presented by LifeSci Capital on behalf of a purported client, the dismal track record of LifeSci Capital and its many affiliates in the biopharmaceutical space, and LifeSci-affiliated funds’ recent nomination of an unqualified dissident slate of nominees for election as directors at the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DFFN.
No results
No recent SID articles mention DFFN.
